Hi Dave, thanks for your efforts to give us more infos to better understand what's going on in the background.Maybe the B-cell tech is ahead of its time and therefore ignored by pharma and investors, like it was with EVs and computers before their breakthroughs.
I would recommend to everyone to watch the NWR presentation from Wednesday. Not just IMU, but RAD and CHM too as they all at some stage are relevant to each other, especially for HER 2.All 3 presentations gave a better insight about the hurdles the 3 comps and others face, some details explaining why certain decisions had to be made.All 3 progress on the clinical fronts while the sp declines. Even at RAD a 6c buy in by the world's biggest radiopharma couldn't get the sp above 50% of that. Strangely, other bio- hopefuls recovered well despite being less advanced.We can't blame the clinical teams, at least they deliver. But something on the financial front must improve, IMU can't be allowed to get as close to the edge as CHM and RAD got.
GLTA
IMU Price at posting:
3.5¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)